骨科患者达肝素钠双场景真实世界研究与药学监护策略分析
刘炎 , 邱季 , 吴国翠 , 李瑞麟 , 陈义昭
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 913 -920.
骨科患者达肝素钠双场景真实世界研究与药学监护策略分析
Dual-scenario real-world study and pharmaceutical care strategy analysis of dalteparin sodium in orthopedic patients
目的: 基于“预防-治疗”双场景分析框架,系统分析骨科患者达肝素钠应用中“预防出血可控、治疗剂量失守”的非对称性风险格局,为骨科患者的精细化抗凝管理提供参考视角。方法: 回顾性纳入某三甲医院骨科 2023 年 9 月至 2025 年 3 月使用达肝素钠的 200 例住院患者,分为预防组(n=185)与治疗组(n=15)。预防组采用多因素 Logistic 回归分析出血事件的独立危险因素,并通过分层分析、倾向性评分匹配(propensity score matching,PSM)验证“指征混杂”假设;治疗组因骨科小样本数据特征,采用 Fisher 确切概率法、Firth 惩罚似然回归、贝叶斯回归分析等多种方法进行探索性分析。结果: 预防组出血事件发生率 22.70%,Caprini 评分≥5 分是出血事件的独立危险因素(OR=8.06,95%CI:1.79~36.20,P=0.007);给药时机不合理为出血事件的保护因素 (OR=0.14, 95%CI: 0.05~ 0.46, P=0.001),分层分析与 PSM 验证结果提示,该关联可能源于“指征混杂”。治疗组患者剂量不足率 93.33%,治疗失败率 21.43%,观察到所有治疗失败的患者均属于剂量不足组,但受限于样本量,其关联强度未能确证。结论: 骨科达肝素钠应用呈现预防场景出血风险集中、治疗场景剂量执行偏差显著的双场景特征,Caprini 评分≥5 分是预防场景下出血风险的关键预警指标,治疗场景中基于体质量分层剂量的执行不足或为治疗失败的潜在诱因。本研究构建的分阶式药学监护体系,可为达肝素钠在骨科的临床应用和优化提供实践参考。
AIM: To analyze the asymmetric risk pattern of "controllable bleeding in prophylaxis versus suboptimal dosing in treatment" during dalteparin sodium use in orthopedic patients using a dual-scenario framework, providing insights for refined anticoagulation management. METHODS: This retrospective study included 200 inpatients receiving dalteparin sodium in an orthopedic department (September 2023 to March 2025). Patients were categorized into prophylaxis (n=185) and treatment (n=15) groups. Multivariate logistic regression identified bleeding risk factors in the prophylaxis group, with stratified analysis and propensity score matching (PSM) assessing potential confounding by indication. For the small treatment group, exploratory analyses (Fisher's exact test, Firth regression, Bayesian methods) were employed. RESULTS: In the prophylaxis group, bleeding events occurred in 22.70% of patients. A Caprini score ≥5 was an independent risk factor (OR=8.06, 95%CI: 1.79–36.20, P=0.007), while inappropriate dosing timing was associated with reduced bleeding risk (OR=0.14, 95%CI: 0.05–0.46, P=0.001). Stratified analysis and PSM suggested confounding by indication. In the treatment group, subtherapeutic dosing was observed in 93.33% of patients, with a 21.43% treatment failure rate. All failures occurred in the subtherapeutic dosing subgroup, though sample size limitations precluded definitive conclusions. CONCLUSION: Dalteparin sodium use in orthopedics shows a dual-scenario pattern: concentrated bleeding risk in prophylaxis and prevalent dosing deviations in treatment. A Caprini score ≥5 serves as a key bleeding risk indicator in prophylaxis. Failure to implement weight-stratified dosing may contribute to therapeutic failure. The proposed tiered pharmaceutical care framework offers practical guidance for optimizing dalteparin sodium use in orthopedic practice.
| [1] |
|
| [2] |
|
| [3] |
中华医学会骨科学分会. 中国骨科大手术静脉血栓栓塞症预防指南[J].中华骨科杂志, 2016, 36(2): 65-71. |
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
Kaatz S, Ahmad D, Spyropoulos AC, |
| [9] |
中国药师协会精准药学工作委员会, 《低分子肝素临床应用中国专家共识》编委会. 低分子肝素临床应用中国专家共识[J/OL].中国现代应用药学, 2026. (2026-01-26)[2026-01-29].https://link.cnki.net/urlid/33.1210.r.20260123.1413.001. |
| [10] |
南京健友生化制药股份有限公司. 达肝素钠注射液说明书[Z].南京: 南京健友生化制药股份有限公司, 2024. (修订日期: 2024 年 11 月 26 日). |
| [11] |
王乔宇, 武明芬, 柳鑫, |
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
Nicolaides AN, Fareed J, Spyropoulos AC, |
| [17] |
|
| [18] |
陈木欣, 梁好, 赵怡迪, |
| [19] |
|
| [20] |
胡美婧, 李满娣, 林奕蝶, |
| [21] |
中国药师协会围手术期用药工作委员会. 围手术期静脉血栓栓塞症防治策略与药学监护专家共识[J].医药导报, 2025, 44(11): 1717-1735. |
安徽省高校自然科学研究项目(2023AH050601)
/
| 〈 |
|
〉 |